In the area of cancer research, a major issue with conventional 2D cell culture is that it cannot reproduce complex in vivo cell-extracellular matrix interactions, nor those between cancer epithelial cells and stromal compartment, which play a crucial role in tumorigenesis and progression. Many 3D culture products have been developed in recent years, including hydrogels, polymeric 3D-printed scaffolds, and electro-spun nanofiber layers. Spheroids, an alternate 3D system used in cancer research, are generated only from epithelial tumor cells which lack the heterogeneous cellular components of tumors. Commercially available 3D basement membrane extracts such as Matrigel®, are costly, require multiple steps for implementation, exhibit batch-to-batch variability, have limited mechanical strength and uncontrolled degradation. There is thus a need for a novel (3D) cell culture system that is customizable, reproducible and better resembles in vivo tissues and tumors. In this communication we present such a 3D kit that is much cheaper, versatile and simpler to use than the aforesaid commercial materials. Our PP-3D-S (plasma-polymer coated, electro-spun 3D scaffold) can mimic the human cancer microenvironment for customized anti-cancer therapeutic screening, or mimic other tissue types for general cell-biological research. As a typical example of PP-3D-S use, designed to evaluate tumor cell migration, a breast-cancer tissue model was simulated as follows: droplets of alginate/gelatin hydrogel containing MDA-MB 231 cancer cells were applied on top of the scaffolds, pre-impregnated with (stromal) fibroblasts. Cell adhesion on plasma-modified PLA mats vastly exceeded than on untreated controls. After three different plasma treatment types (NH3, O2, L-PPE: N, amine-rich PP), the first was the best in regard to tumor cell migration to the scaffold surfaces after 7 days of culture. In two different sets of cancer drug screening experiments, “PP-3D-S” and Matrigel®, migrated surviving tumor cells were compared after exposure to varying dosages of Doxorubicin; numerical outcomes were very similar, ca.75% reduction with 0.5uM. Clearly, PP-3D-S satisfies the needs expressed above